🇺🇸 FDA
Pipeline program

B-MAD chemotherapy

TLSG-2017-T01

Phase 2 small_molecule completed

Quick answer

B-MAD chemotherapy for Extranodal NK/T-cell Lymphoma is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Extranodal NK/T-cell Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials